IBEX 35
10.729,50 -35,50 (-0,33%) Euro Stoxx 50
4.918,09 -18,48 (-0,37%) Dólar/Euro
1,0661 +0,0015 (+0,14%) Petróleo Brent
87,20 +0,09 (+0,10%) Oro
2.406,70 +8,70 (+0,36%) Bitcoin EUR
60.217,61 +1.664,41 (+2,84%)
Fate Therapeutics, Inc. (FATE)
Después del cierre:
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 181
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. J. Scott Wolchko | Founder, CEO, President & Director | 645k | 3,85M | 1970 |
| Mr. Edward J. Dulac III | Chief Financial Officer | 455k | N/A | 1976 |
| Ms. Cindy R. Tahl J.D. | General Counsel, Corporate Secretary & Compliance Officer | 455k | 3,89M | 1973 |
| Dr. Bahram Valamehr Ph.D. | Chief Research & Development Officer | 455k | 1,39M | 1977 |
| Mr. Jim Beitel M.B.A. | Senior Vice President of Corporate Development | N/A | N/A | N/A |
| Dr. Jerome Bressi Ph.D. | Senior Vice President of Regulatory & Quality | N/A | N/A | N/A |
| Dr. Barbara Hickingbottom | Senior VP of Clinical Development | N/A | N/A | N/A |
Descripción
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Gobierno corporativo
El ISS Governance QualityScore de Fate Therapeutics, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 5; Derechos de los accionistas: 8; Compensación: 7.
